Simone Ummarino

Staff Scientist II

Tufts University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Year:

2026

Year:

2026

Year:

2025

Advancements in genome sequencing technologies have uncovered the multifaceted roles of long non-coding RNAs (lncRNAs) in human cells. Recent discoveries have identified lncRNAs as major players in gene regulatory pathways, highlighting their pivotal role in human cell growth and development. Their dysregulation is implicated in the onset of genetic disorders and age-related diseases, including cancer. Specifically, they have been found to orchestrate molecular mechanisms impacting epigenetics, including DNA methylation and hydroxymethylation, histone modifications, and chromatin remodeling, thereby significantly influencing gene expression. This review provides an overview of the current knowledge on lncRNA-mediated epigenetic regulation of gene expression, emphasizing the biomedical implications of lncRNAs in the development of different types of cancers and genetic diseases.

Year:

2025

Small activating RNAs are short double-stranded RNAs designed to upregulate transcription of target genes. By this virtue, they can be used to restore expression of genes frequently silenced in cancer. AW1-51 (also referred to as CEBPA-51), the first small activating RNA therapeutic to enter clinical evaluation, has demonstrated biological activity and safety in Phase II trials for hepatocellular carcinoma, both as monotherapy and in combination with sorafenib, and in Phase 1a/1b in combination with pembrolizumab for patients with advanced solid tumors. It targets the master regulator CCAAT enhancer-binding protein alpha, abnormally silenced by DNA methylation in a wide range of hematological and non-hematological malignancies. However, the molecular events enabling this mechanism are only partially elucidated. In this study, we uncovered the molecular basis for AW1-51-induced transcriptional reactivation of CCAAT enhancer-binding protein alpha demonstrating that by directly promoting DNA demethylation of its promoter restores its expression, protein synthesis, and consequently cell differentiation. These findings unveil AW1-51 as a prototype for RNA-based precision medicine enabling conditional expression of CCAAT enhancer-binding protein alpha in diseases characterized by aberrant gene silencing and extending its potential therapeutic impact beyond cancer.

Year:

2025

Year:

2023

Collaborators (11)

Alexander Ebralidze

Staff Scientist II

Beth Israel Deaconess Medical Center

UNITED STATES
View details

Angela Di Baldassarre

Head, Reprogramming and Cell Differentiation Laboratory Center for Advanced Studies and Technology

University of Chieti-Pescara

ITALY
View details

Annalisa Di Ruscio

University of Eastern Piedmont

ITALY
View details

Susumu Kobayashi

Beth Israel Deaconess Medical Center

UNITED STATES
View details

pedro p. medina

Head of Research Group

Universidad de Granada

SPAIN
View details

Miwako Kakiuchi

The Univeristy of Tokyo

JAPAN
View details

Daniel G. Tenen

Harvard University

UNITED STATES
View details

Hiroko Oda

University of Tokyo

JAPAN
View details

Nagy HABIB

Imperial College London

UNITED KINGDOM
View details

Madhura Deshpande

Assistant Professor of Research in Reproductive medicine & Obstetrics and Gynecology

Weill Cornell Medicine

UNITED STATES
View details

barbara ghinassi

Professore Associato

University of Chieti-Pescara

ITALY
View details